HyperBranch Medical Technology

What HyperBranch Medical Technology does

HyperBranch Medical Technology is a privately held medical device company founded in 2003 and headquartered in Durham, North Carolina, that develops and commercializes products for the traumatic or surgically-induced wound market. The company's core offering centers on its Adherus line of hydrogel-based dural sealants — specifically the Adherus AutoSpray Dural Sealant and the Adherus AutoSpray ET Dural Sealant (an extended-tip applicator variant) — which are indicated for patients aged 13 and older as adjuncts to standard dural repair methods (such as sutures) to provide watertight closure during cranial procedures. The hydrogel technology is engineered to maintain burst pressure strength above physiological intracranial pressure and to absorb over approximately 90 days, with clinical evidence from a prospective, randomized, controlled, multicenter pivotal trial demonstrating 99.1% effectiveness in preventing cerebrospinal fluid (CSF) leaks at 14-day follow-up and 91.2% overall success rate (non-inferiority p=0.005) versus active control.

The company's go-to-market is built on an enterprise field sales model executed through Stryker's established medical device distribution network, targeting neurosurgical and craniomaxillofacial departments at hospitals and surgical centers globally. HyperBranch operates with 11-50 employees under the leadership of John Conn, President & CEO and member of the Board of Directors. The company has raised approximately $18.6 million across multiple funding rounds between 2005 and 2013, with investors including The Aurora Funds (lead investor in the 2005 Series 2) and H.I.G. Capital. Pricing is not publicly disclosed; healthcare facilities request product information through Stryker's sales channel, and products are sold as one-time-purchase medical device units consumed during cranial surgical procedures.

Name

HyperBranch Medical Technology

Website

https://hyperbranch.com

Company type

Private

Founded year

2003

Headcount range

11–50 employees

Short description

HyperBranch Medical Technology is a Durham, NC-based medical device company that develops hydrogel-based dural sealants (Adherus AutoSpray line) for watertight closure in cranial procedures, commercialized through Stryker's distribution network to neurosurgical and craniomaxillofacial hospital departments.

Ownership category

akta.pro rank

Product category

Neurosurgical Medical Devices

NAICS

Adhesive Manufacturing (32552)

SIC

Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Wound Closure & Securement (Sutures, Staples, Tissue Adhesives, Skin Closure Strips) (HLAHALAD)

akta.pro secondary industry

Surgical Stapling, Suturing & Hemostasis (Staplers, Clips, Sealants, Tourniquets) (HLAHADAL)

Keywords

• Dural sealants
• Neurosurgical devices
• Hydrogel sealants
• Cranial closure products
• Wound closure medical devices

Headquarters

HQ city

Durham

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Personnel, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Medical Device Sales: Sale of medical device products (dural sealants) to healthcare facilities through Stryker's distribution network. Products are sold as adjuncts to surgical procedures.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

HyperBranch Medical Technology develops and commercializes hydrogel-based dural sealants—Adherus AutoSpray Dural Sealant and Adherus AutoSpray ET Dural Sealant—used as an adjunct to sutures to achieve watertight closure of the dura mater during cranial neurosurgical and craniomaxillofacial procedures, addressing the traumatic or surgically-induced wound market. The sealants are distributed through Stryker's sales channel and are targeted at neurosurgery and skull-base surgical departments in hospitals and surgical centers.

Product overview

HyperBranch Medical Technology's product portfolio, as represented in the available source data, consists of medical device products for cranial and neurosurgical procedures. The core offering includes the Adherus AutoSpray and Adherus AutoSpray ET Dural Sealant product lines — hydrogel-based sealants designed as adjuncts to standard dural repair methods to provide watertight closure during cranial procedures. These products are positioned within the craniomaxillofacial and cranial closure product categories. Note: The source data shows these products as part of Stryker's craniomaxillofacial portfolio; the relationship between HyperBranch Medical Technology and Stryker is not specified in the source material.

Differentiator

Problem solved

Functional benefit

Products and services

• Adherus AutoSpray Dural Sealant

Quantifiable outcome

• 99.1% effectiveness in preventing CSF leaks through 14 days post-operative follow-up
• +3 more outcomes

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature2 records

Scale indicators3 records

Recent moves5 records

Expansion highlights3 records

Direct peers

• Integra LifeSciences: Integra markets DuraSeal, the leading competing hydrogel/polymer dural sealant used for watertight closure in cranial and spinal procedures. Most directly comparable competitor to Adherus, serving the same neurosurgical customer base with the same adjunct-to-sutures value proposition.

Broad incumbents

• Baxter International: Baxter owns Tisseel and Floseal, two widely used surgical sealants and hemostats used across multiple surgical specialties. Comparable as a broader surgical sealant incumbent with overlapping operating-room customers, though its portfolio spans far beyond cranial procedures.
• Ethicon (Johnson & Johnson): Ethicon markets Evicel and other surgical sealants/hemostats and is the dominant surgical sutures supplier globally. Comparable as an incumbent with deep surgeon relationships and competing sealant chemistries in the same cranial and broader neurosurgical workflows.
• Medtronic: Medtronic has a large neurosurgical and cranial portfolio and historically has competed in the dural repair space through legacy products and partnerships. Comparable as a broad neurosurgical incumbent with overlapping surgical-suite customers and resources to consolidate the sealant category.
• B. Braun (Aesculap): B. Braun's Aesculap division supplies surgical instruments, dural substitutes, and sealants used in neurosurgical procedures. Comparable as a broad neurosurgical device incumbent with overlapping surgical-suite customers and an interest in the dural closure category.

Emerging players

• Tissuemed: Tissuemed develops tissue adhesives and sealants, including products positioned for dural and surgical sealing applications. Comparable as a smaller specialist player in surgical sealants with overlapping chemistry-driven value proposition but narrower geographic/commercial reach than Adherus via Stryker.
• Polyganics: Polyganics develops bioresorbable polymer-based sealants and devices for neurosurgical and peripheral nerve repair applications. Comparable as an emerging polymer-chemistry specialist with overlapping bioresorbable sealant technology relevant to the same cranial and nerve-repair use cases.

Others

• Stryker: Stryker is HyperBranch's exclusive distribution partner for the Adherus line and also operates a broad neurosurgical and craniomaxillofacial portfolio. Relevant as the commercial channel that defines Adherus's reach and as a potential strategic acquirer of HyperBranch.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

• YouTubeyoutube.com/user/stryker
• Facebookfacebook.com/strykercareers
• LinkedInlinkedin.com/company/hyperbranch-medical-tech-inc
• Instagraminstagram.com/strykercareers?igshid=1wcmnukna7ee7

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds9 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about HyperBranch Medical Technology